HB 1426 creates a new permit for clinical research pharmacies in Maryland, which are facilities specifically designed to conduct clinical trials. It allows healthcare providers to own these pharmacies under strict conditions, including requiring a licensed pharmacist to be on-site during all operating hours and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations or entities from being classified as "practice of medicine," meaning trial staff no longer need individual medical licenses for their trial-related work. This change aims to streamline clinical research by removing a regulatory barrier that previously required individual licensing for trial staff.
HB 222 requires Maryland public schools and colleges to update policies and education programs to address opioid overdoses. It mandates schools to store naloxone, allow authorized staff and students to possess it, and provide liability protection for good-faith use during overdoses. The bill also adds naloxone's life-saving role to K-12 drug prevention curricula (starting in third grade) and requires annual parent notifications about school naloxone policies. Additionally, schools must report overdose incidents requiring naloxone use to the State Department. This affects all public K-12 schools and state-funded colleges.
HB 598 creates a temporary license for internationally trained physicians to practice medicine in Maryland under specific conditions. It allows the State Board of Physicians to issue a 3-year license (non-renewable) to doctors who hold a WHO-recognized medical degree outside the U.S., completed 2 years of equivalent postgraduate training, practiced medicine for 5 of the last 7 years abroad, passed U.S. medical exams (USMLE Steps 1-3), and meet other criteria like English proficiency and Maryland residency. The license requires physicians to pursue full licensure through board-established pathways after the temporary period ends. This directly affects internationally trained doctors seeking to work in Maryland’s healthcare system, providing a structured but limited pathway to practice.
HB 633 requires Maryland health insurers, nonprofit health plans, and health maintenance organizations to cover salpingectomy (surgical removal of fallopian tubes) as a preventive measure for ovarian cancer. It prohibits these insurers from charging copayments, coinsurance, or deductibles for this specific procedure, ensuring no out-of-pocket costs for covered individuals. The exception applies only to high-deductible health plans under federal law, allowing the deductible to apply to the procedure in those cases. This law directly affects women eligible for preventive care and the health insurance providers operating in Maryland.
SB 489 modifies Maryland's licensing rules for physicians trained at international medical schools. It exempts applicants who provide evidence of completing two years of postgraduate training accredited by ACGME-I or another board-recognized body from standard educational requirements. These physicians would be permitted to practice medicine only during their initial license term under mandatory supervision, as specified by the Board. The bill takes effect October 1, 2026, directly affecting international medical graduates meeting these specific training criteria.
HB 1167 requires Maryland's Department of Health to replace its outdated Medicaid computer system with a modern, flexible system by 2028. The new system must maintain all current Medicaid functions - including processing medical/dental/pharmacy claims, provider enrollment, and beneficiary inquiries - while meeting federal security and performance standards. The bill mandates integration with existing Medicaid systems by January 2027 and full replacement of the old system by January 2028, subject to federal approval. This change directly affects Medicaid beneficiaries and healthcare providers through more reliable service delivery.
SB 515 requires Maryland's Health Services Cost Review Commission to consider all operational costs incurred by health facilities - including expenses for physicians and other providers without corresponding billing revenue - when setting hospital rates. This affects hospitals and health facilities operating under Maryland's all-payer model, as the Commission must now factor in full costs during rate reviews. The bill amends existing law to mandate that the Commission evaluate facility financial health and certify rates based on complete cost accounting, rather than excluding certain expenses. This change ensures rates more accurately reflect actual facility operations, including costs for professional services that previously weren't fully counted.
HB 1014 defines "danger to the life or safety of the individual or of others" for Maryland's mental health law, directly affecting individuals with mental disorders who might face involuntary admission. It specifies four concrete scenarios that constitute this danger: causing bodily harm, engaging in conduct leading to criminal involvement, inability to meet basic needs (food, shelter, medical care), or substantial deterioration in judgment that impairs treatment decisions. The definition requires a "substantial risk" considering the person's current condition and available history, replacing the prior standard. This change clarifies the legal threshold for involuntary hospitalization and emergency evaluations under Maryland law.
HB 813 authorizes Maryland's Medicaid program (Maryland Medical Assistance Program) to cover comprehensive obesity treatment, including intensive behavioral therapy, bariatric surgery, and FDA-approved weight management medications, starting January 1, 2027. The bill requires the Maryland Department of Health to notify Medicaid recipients if it chooses to provide this coverage and mandates a report to the legislature by November 1, 2027, on implementation progress. This directly affects Medicaid recipients with obesity by expanding covered treatments beyond current scope. The program may use standard utilization management processes (like for other conditions) to assess medical necessity but is not required to offer the coverage.
HB 883 prohibits AI developers from making or causing AI to make claims that the AI is a behavioral health provider or can deliver behavioral health care services. It requires AI sold to Maryland consumers to include clear notices stating users are interacting with AI (not a human) and to detect suicidal thoughts or self-harm, automatically referring users to crisis services. Violations carry civil penalties up to $1 million per offense, with funds directed to Maryland’s Behavioral Health Workgroup Investment Fund. The law directly affects AI developers and sellers operating in Maryland, focusing on preventing misleading AI interactions in mental health contexts.